Skip to main content
Top
Published in: American Journal of Clinical Dermatology 3/2020

01-06-2020 | Dermatomyositis | Review Article

Dermatomyositis: An Update on Diagnosis and Treatment

Authors: Gabriela A. Cobos, Alisa Femia, Ruth Ann Vleugels

Published in: American Journal of Clinical Dermatology | Issue 3/2020

Login to get access

Abstract

Dermatomyositis is a rare inflammatory disease with characteristic cutaneous findings and varying amounts of systemic involvement. Patients may present with skin disease alone, have concomitant muscle disease, or have extracutaneous manifestations such as pulmonary disease or an associated malignancy. Given such diverse presentations, dermatomyositis is both a diagnostic and therapeutic challenge. However, a prompt diagnosis is of utmost importance to institute adequate therapy and screen patients for an associated malignancy. Dermatologists should play a crucial role in the diagnosis and management of patients with dermatomyositis as cutaneous disease tends to be chronic, negatively impact quality of life, and be more recalcitrant to therapy. In this review, we discuss diagnosis, with a focus on myositis-specific antibodies and their associated phenotypes. We also review therapies available for this often refractory skin disease.
Literature
9.
go back to reference Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387–408.PubMedCrossRef Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387–408.PubMedCrossRef
10.
go back to reference Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.PubMedCrossRef Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.PubMedCrossRef
22.
go back to reference Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621–5. https://doi.org/10.1136/ard.2008.097162.CrossRefPubMed Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621–5. https://​doi.​org/​10.​1136/​ard.​2008.​097162.CrossRefPubMed
41.
go back to reference Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017;7:188.PubMedPubMedCentralCrossRef Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017;7:188.PubMedPubMedCentralCrossRef
55.
go back to reference Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32. https://doi.org/10.1002/art.33379.CrossRefPubMed Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32. https://​doi.​org/​10.​1002/​art.​33379.CrossRefPubMed
61.
go back to reference Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.PubMedCrossRef Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.PubMedCrossRef
62.
go back to reference Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6(1):9–13.PubMedCrossRef Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6(1):9–13.PubMedCrossRef
73.
go back to reference Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994;131(2):205–8.PubMedCrossRef Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994;131(2):205–8.PubMedCrossRef
80.
go back to reference Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12(1):50–2.PubMed Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12(1):50–2.PubMed
81.
go back to reference Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol. 2003;148(3):595–6.PubMedCrossRef Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol. 2003;148(3):595–6.PubMedCrossRef
87.
go back to reference Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1 Suppl.):S39–46.PubMedCrossRef Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1 Suppl.):S39–46.PubMedCrossRef
89.
go back to reference Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592–600.PubMedCrossRef Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592–600.PubMedCrossRef
90.
go back to reference James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol. 1985;12(6):1214–6.PubMed James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol. 1985;12(6):1214–6.PubMed
91.
go back to reference Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, et al. Dermatomyositis without muscle weakness: long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol. 1995;131(12):1381–5.PubMedCrossRef Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, et al. Dermatomyositis without muscle weakness: long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol. 1995;131(12):1381–5.PubMedCrossRef
92.
go back to reference Cox NH. Amyopathic dermatomyositis, photosensitivity and hydroxychloroquine. Br J Dermatol. 1995;132(6):1016–7.PubMed Cox NH. Amyopathic dermatomyositis, photosensitivity and hydroxychloroquine. Br J Dermatol. 1995;132(6):1016–7.PubMed
93.
go back to reference Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol. 1998;38(3):397–404.PubMedCrossRef Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol. 1998;38(3):397–404.PubMedCrossRef
95.
go back to reference Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231–3 (discussion 3).PubMedCrossRef Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231–3 (discussion 3).PubMedCrossRef
100.
go back to reference Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994;370:411–6.PubMedCrossRef Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994;370:411–6.PubMedCrossRef
102.
go back to reference Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet. 1968;2(7566):485–8.PubMedCrossRef Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet. 1968;2(7566):485–8.PubMedCrossRef
103.
go back to reference Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1(2):99–102.PubMedCrossRef Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1(2):99–102.PubMedCrossRef
104.
go back to reference Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5 Pt 1):754–7.PubMedCrossRef Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5 Pt 1):754–7.PubMedCrossRef
105.
go back to reference Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67–71.PubMedCrossRef Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67–71.PubMedCrossRef
106.
go back to reference Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD. The value of methotrexate in dermatomyositis. J Am Acad Dermatol. 1998;38(1):130–2.PubMed Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD. The value of methotrexate in dermatomyositis. J Am Acad Dermatol. 1998;38(1):130–2.PubMed
108.
go back to reference Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin N Am. 1997;23(4):917–37.CrossRef Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin N Am. 1997;23(4):917–37.CrossRef
109.
go back to reference Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–8.PubMed Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–8.PubMed
111.
go back to reference Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):824–9.PubMed Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):824–9.PubMed
112.
go back to reference Vleugels RA, Callen JP. Dermatomyositis: current and future treatments. Expert Rev Dermatol. 2009;4:581–94.CrossRef Vleugels RA, Callen JP. Dermatomyositis: current and future treatments. Expert Rev Dermatol. 2009;4:581–94.CrossRef
114.
go back to reference Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.PubMedCrossRef Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.PubMedCrossRef
115.
go back to reference Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27(6):1542–5.PubMed Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27(6):1542–5.PubMed
121.
go back to reference Hisanaga J, Kotani T, Fujiki Y, Yoshida S, Takeuchi T, Makino S. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis. 2017;20(12):2182–5. https://doi.org/10.1111/1756-185X.13136.CrossRefPubMed Hisanaga J, Kotani T, Fujiki Y, Yoshida S, Takeuchi T, Makino S. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis. 2017;20(12):2182–5. https://​doi.​org/​10.​1111/​1756-185X.​13136.CrossRefPubMed
140.
go back to reference Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230–7.PubMed Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230–7.PubMed
141.
go back to reference Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol. 2005;23(5):724.PubMed Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol. 2005;23(5):724.PubMed
142.
go back to reference Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44(11):1197–9.PubMedCrossRef Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44(11):1197–9.PubMedCrossRef
144.
go back to reference Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005;23(5):707–10.PubMed Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005;23(5):707–10.PubMed
145.
go back to reference Ramirez G, Asherson RA, Khamashta MA, Cervera R, D’Cruz D, Hughes GR. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum. 1990;20(2):114–20.PubMedCrossRef Ramirez G, Asherson RA, Khamashta MA, Cervera R, D’Cruz D, Hughes GR. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum. 1990;20(2):114–20.PubMedCrossRef
146.
go back to reference Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36(3):319–24.PubMedCrossRef Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36(3):319–24.PubMedCrossRef
147.
go back to reference Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95–102.PubMedCrossRef Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95–102.PubMedCrossRef
151.
go back to reference Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc). 2006;127(18):697–701.PubMedCrossRef Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc). 2006;127(18):697–701.PubMedCrossRef
153.
go back to reference Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med. 2008;47(21):1935–40.PubMedCrossRef Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med. 2008;47(21):1935–40.PubMedCrossRef
156.
go back to reference Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol. 2002;41(3):182–4.PubMedCrossRef Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol. 2002;41(3):182–4.PubMedCrossRef
157.
go back to reference Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994;19(4):367.PubMedCrossRef Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994;19(4):367.PubMedCrossRef
160.
go back to reference Zuber M, John S, Pfreundschuh M, Gause A. A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum. 1996;39(8):1419–22.PubMedCrossRef Zuber M, John S, Pfreundschuh M, Gause A. A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum. 1996;39(8):1419–22.PubMedCrossRef
162.
173.
go back to reference Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9):1802–4.PubMed Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9):1802–4.PubMed
174.
go back to reference Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2010;48(3):240–6.PubMed Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2010;48(3):240–6.PubMed
181.
go back to reference Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39(1):192–4.PubMed Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39(1):192–4.PubMed
Metadata
Title
Dermatomyositis: An Update on Diagnosis and Treatment
Authors
Gabriela A. Cobos
Alisa Femia
Ruth Ann Vleugels
Publication date
01-06-2020
Publisher
Springer International Publishing
Keyword
Dermatomyositis
Published in
American Journal of Clinical Dermatology / Issue 3/2020
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-020-00502-6

Other articles of this Issue 3/2020

American Journal of Clinical Dermatology 3/2020 Go to the issue